ATE557041T1 - Peptid-vakzinen gegen streptokokken der gruppe a - Google Patents

Peptid-vakzinen gegen streptokokken der gruppe a

Info

Publication number
ATE557041T1
ATE557041T1 AT02734477T AT02734477T ATE557041T1 AT E557041 T1 ATE557041 T1 AT E557041T1 AT 02734477 T AT02734477 T AT 02734477T AT 02734477 T AT02734477 T AT 02734477T AT E557041 T1 ATE557041 T1 AT E557041T1
Authority
AT
Austria
Prior art keywords
peptides
antibodies
compositions
vaccines
relates
Prior art date
Application number
AT02734477T
Other languages
English (en)
Inventor
Bernard Beall
George Carlone
Jacquelyn Sampson
Edwin Ades
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE557041T1 publication Critical patent/ATE557041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02734477T 2001-05-18 2002-05-20 Peptid-vakzinen gegen streptokokken der gruppe a ATE557041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29183501P 2001-05-18 2001-05-18
PCT/US2002/015909 WO2002094851A2 (en) 2001-05-18 2002-05-20 Peptide vaccines against group a streptococci

Publications (1)

Publication Number Publication Date
ATE557041T1 true ATE557041T1 (de) 2012-05-15

Family

ID=23122046

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734477T ATE557041T1 (de) 2001-05-18 2002-05-20 Peptid-vakzinen gegen streptokokken der gruppe a

Country Status (5)

Country Link
US (5) US7407664B2 (de)
EP (1) EP1399181B1 (de)
AT (1) ATE557041T1 (de)
CA (2) CA2447599C (de)
WO (1) WO2002094851A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
ATE557041T1 (de) * 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
US7709009B2 (en) * 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (de) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogene und therapeutische zusammensetzungen für pyogene streptokokken
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
EP2173902A4 (de) * 2007-07-03 2013-01-09 Mt Sinai Hospital Therapeutika und diagnostika für gruppe-a-streptokokken
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP2443250B8 (de) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Komplement-vermittelte antikörper-abhängige und opsonische bakterienassays mit hohem durchlauf
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
EP2953641A4 (de) 2013-02-11 2016-11-16 Univ Tennessee Res Foundation Gruppe-a-streptokokken-m-verwandte proteine und verfahren zur verwendung
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
CN112449603A (zh) * 2018-05-16 2021-03-05 格里菲斯大学 链球菌中毒性休克综合征
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
CA3224156A1 (en) 2021-06-28 2023-01-05 VST LLC dba Medgene Labs Sapovirus vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
EP0618813B1 (de) 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
DE69331733T2 (de) * 1992-09-16 2002-08-22 The University Of Tennessee Research Corp., Knoxville Rekombinantes vielwertiges m-protein-vakzin
DE69836744T2 (de) * 1997-09-12 2007-10-04 University Of Tennessee Research Foundation, Knoxville Gruppe a streptokokken-impfstoff
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
ATE557041T1 (de) * 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a

Also Published As

Publication number Publication date
US7883710B2 (en) 2011-02-08
CA2881980A1 (en) 2002-11-28
US20130202635A1 (en) 2013-08-08
EP1399181A2 (de) 2004-03-24
CA2447599A1 (en) 2002-11-28
US7407664B2 (en) 2008-08-05
US20110110969A1 (en) 2011-05-12
US20120177685A1 (en) 2012-07-12
WO2002094851A2 (en) 2002-11-28
US8637050B2 (en) 2014-01-28
US20050220808A1 (en) 2005-10-06
EP1399181A4 (de) 2006-06-28
US8420107B2 (en) 2013-04-16
WO2002094851A3 (en) 2003-10-30
CA2447599C (en) 2015-04-28
US20080279880A1 (en) 2008-11-13
EP1399181B1 (de) 2012-05-09

Similar Documents

Publication Publication Date Title
EP1399181A4 (de) Peptid-vakzinen gegen streptokokken der gruppe a
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
ATA17892000A (de) Vakzin-zusammensetzung
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
WO2001079274A8 (en) Tuberculosis antigens and methods of use thereof
EP1530637A4 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2009074318A3 (en) Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
EP1700913A4 (de) Fluoreszenzproteine
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
DE60127113D1 (de) Gd3 mimetische peptide
DE60234475D1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
WO2003038061A3 (en) Ehrlichia disulfide bond formation proteins and uses thereof
ATE338126T1 (de) Dna-sequenz und rekombinante herstellung eines graminaen-allergens
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method